Tiziana Life Sciences Ltd. (TLSA), a London-based biotechnology company, Thursday announced it does not plan to pursue capital-raising activities in the proximate future.
Building on yesterday's announcement of discovering new immune biomarkers in non-active secondary progressive multiple sclerosis widely known as "na-SPMS" patients treated with nasal foralumab, the Company has decided not to pursue capital-raising activities in the near term.
TLSA is currently trading at $0.7140 or 10.4028% lower on the Nasdaq Capital Market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.